Antigenix Therapeutics

Executive Summary

Antigenix Therapeutics is a private, preclinical-stage biotechnology company founded in 2016 and headquartered in New York, USA. The company specializes in developing novel antibody-drug conjugates (ADCs) targeting tumor-specific markers for aggressive cancers with limited treatment options. By leveraging unique antigens, Antigenix aims to expand the therapeutic reach of ADCs beyond current indications, potentially offering safer and more effective therapies. Despite being in early stages, the company's focused strategy and experienced leadership position it to address significant unmet medical needs. However, as a private preclinical entity, it faces typical risks including funding requirements, regulatory hurdles, and technical challenges in ADC development.

Upcoming Catalysts (preview)

• Q3 2026IND Filing for Lead ADC Candidate40% success
• H1 2026Presentation of Preclinical Efficacy Data at Major Conference70% success
• TBDStrategic Partnership or Licensing Deal30% success